Publikation bearbeiten
A new allergic rhinitis therapy (MP29-02) is more effective than current first line monotherapies in providing allergic rhinitis patients relief from their nasal and ocular symptoms (rTNSS, rT5SS, rT7SS)
(
Zeitschriftenartikel
)